Legal Representation
Attorney
Jenevieve Maerker
USPTO Deadlines
Application History
43 events| Date | Code | Type | Description |
|---|---|---|---|
| Dec 19, 2022 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Dec 19, 2022 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| May 13, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| May 12, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| May 12, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED |
| May 5, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 5, 2022 | EXT5 | S | SOU EXTENSION 5 FILED |
| Nov 3, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Nov 1, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 1, 2021 | EXT4 | S | SOU EXTENSION 4 FILED |
| Nov 1, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Apr 30, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 28, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 28, 2021 | EXT3 | S | SOU EXTENSION 3 FILED |
| Apr 28, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Nov 3, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 30, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 30, 2020 | EXT2 | S | SOU EXTENSION 2 FILED |
| Oct 30, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Mar 10, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 6, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 6, 2020 | EXT1 | S | SOU EXTENSION 1 FILED |
| Mar 6, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Nov 12, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Sep 17, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Sep 17, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Aug 28, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 14, 2019 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Aug 14, 2019 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Aug 14, 2019 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Aug 14, 2019 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Aug 14, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 13, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Aug 13, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 8, 2019 | ALIE | A | ASSIGNED TO LIE |
| Aug 1, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jul 1, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jul 1, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jul 1, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jun 28, 2019 | DOCK | D | ASSIGNED TO EXAMINER |
| May 7, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| May 6, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Apr 23, 2019 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Ocular pharmaceuticals
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development of pharmaceutical preparations and medicines; Research and development in the pharmaceutical and biotechnology fields
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of a design featuring a circle containing blood vessels and five circles representing cells. The left half of the circle is grey and the right half is red, and the details and background of the mark are presented in negative space that will appear in the color of the surface upon which it is placed. The red stylized term "INGENIA" is presented to the right of the design over the grey stylized wording "THERAPEUTICS".
Color Claim
The color(s) red, grey is/are claimed as a feature of the mark.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"
USPTO Documents
Loading USPTO documents...